Ultragenyx's (RARE) Crysvita Royalties Sale is "Value Add, Extends Cash Runway into Profitability" - Truist Securities Bullish on Stock
Tweet Send to a Friend
Truist Securities analyst Joon Lee reiterated a Buy rating and $185.00 price target on Ultragenyx Pharma (NASDAQ: RARE), following the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
